tiprankstipranks
Trending News
More News >
Ovid Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
PremiumRatingsOvid Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
1M ago
Ovid Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
Premium
Ratings
Ovid Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
1M ago
Ovid Therapeutics reports Q1 EPS (14c), consensus (13c)
Premium
The Fly
Ovid Therapeutics reports Q1 EPS (14c), consensus (13c)
1M ago
Ovid Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
PremiumThe FlyOvid Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
3M ago
Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer
Premium
The Fly
Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer
3M ago
Ovid Therapeutics price target lowered to $3 from $4 at Wedbush
Premium
The Fly
Ovid Therapeutics price target lowered to $3 from $4 at Wedbush
3M ago
Ovid Therapeutics appoints Papadopoulos to board of directors
PremiumThe FlyOvid Therapeutics appoints Papadopoulos to board of directors
4M ago
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’
Premium
The Fly
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’
5M ago
Ovid Therapeutics upgraded to Outperform from Perform at Oppenheimer
Premium
The Fly
Ovid Therapeutics upgraded to Outperform from Perform at Oppenheimer
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100